Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MK-2206
i
Other names:
MK 2206 Accurin, BIND-2206 Accurin, BIND 2206 , NSC-749607, BIND2206, MK2206, MK-2206, MK 2206, BIND-2206
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(27)
News
Trials
Company:
Merck (MSD)
Drug class:
AKT inhibitor
Related drugs:
‹
capivasertib (37)
RG7440 (27)
chidamide (23)
LY294002 (7)
TAS-117 (7)
pexidartinib (6)
ONC201 (5)
DIACC3010 (5)
GSK690693 (3)
enzastaurin (3)
GDC-0084 (3)
CCT128930 (2)
SBI-756 (2)
UCN-01 (1)
DFN-529 (1)
EC-70124 (1)
LY2780301 (1)
SBI-726 (1)
nelfinavir (1)
D21266 (1)
CBL0102 (1)
LAE003 (1)
A 443654 (0)
AT7867 (0)
HV-107 (0)
antroquinonol (0)
MKC-1 (0)
SR13668 (0)
TAS0612 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
PBI-05204 (0)
NV06 (0)
PX 866 (0)
PTX-200 (0)
capivasertib (37)
RG7440 (27)
chidamide (23)
LY294002 (7)
TAS-117 (7)
pexidartinib (6)
ONC201 (5)
DIACC3010 (5)
GSK690693 (3)
enzastaurin (3)
GDC-0084 (3)
CCT128930 (2)
SBI-756 (2)
UCN-01 (1)
DFN-529 (1)
EC-70124 (1)
LY2780301 (1)
SBI-726 (1)
nelfinavir (1)
D21266 (1)
CBL0102 (1)
LAE003 (1)
A 443654 (0)
AT7867 (0)
HV-107 (0)
antroquinonol (0)
MKC-1 (0)
SR13668 (0)
TAS0612 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
PBI-05204 (0)
NV06 (0)
PX 866 (0)
PTX-200 (0)
›
Associations
(27)
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
MK-2206
Sensitive: C2 – Inclusion Criteria
MK-2206
Sensitive
:
C2
MK-2206
Sensitive: C2 – Inclusion Criteria
MK-2206
Sensitive
:
C2
KRAS G12D
Pancreatic Cancer
KRAS G12D
Pancreatic Cancer
MK-2206
Sensitive: C4 – Case Studies
MK-2206
Sensitive
:
C4
MK-2206
Sensitive: C4 – Case Studies
MK-2206
Sensitive
:
C4
PTEN mutation
Pancreatic Cancer
PTEN mutation
Pancreatic Cancer
MK-2206
Sensitive: C4 – Case Studies
MK-2206
Sensitive
:
C4
MK-2206
Sensitive: C4 – Case Studies
MK-2206
Sensitive
:
C4
MLL rearrangement
Childhood B Acute Lymphoblastic Leukemia
MLL rearrangement
Childhood B Acute Lymphoblastic Leukemia
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
FGFR2 N549K
Endometrial Cancer
FGFR2 N549K
Endometrial Cancer
futibatinib + MK-2206
Sensitive: D – Preclinical
futibatinib + MK-2206
Sensitive
:
D
futibatinib + MK-2206
Sensitive: D – Preclinical
futibatinib + MK-2206
Sensitive
:
D
HRAS G13R
Thyroid Gland Anaplastic Carcinoma
HRAS G13R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
PIK3CA mutation
Thyroid Gland Carcinoma
PIK3CA mutation
Thyroid Gland Carcinoma
temsirolimus + MK-2206
Sensitive: D – Preclinical
temsirolimus + MK-2206
Sensitive
:
D
temsirolimus + MK-2206
Sensitive: D – Preclinical
temsirolimus + MK-2206
Sensitive
:
D
PTEN deletion
Lung Adenocarcinoma
PTEN deletion
Lung Adenocarcinoma
selumetinib + MK-2206
Sensitive: D – Preclinical
selumetinib + MK-2206
Sensitive
:
D
selumetinib + MK-2206
Sensitive: D – Preclinical
selumetinib + MK-2206
Sensitive
:
D
BRAF V600E
Melanoma
BRAF V600E
Melanoma
selumetinib + MK-2206
Sensitive: D – Preclinical
selumetinib + MK-2206
Sensitive
:
D
selumetinib + MK-2206
Sensitive: D – Preclinical
selumetinib + MK-2206
Sensitive
:
D
KRAS mutation
Lung Adenocarcinoma
KRAS mutation
Lung Adenocarcinoma
selumetinib + MK-2206
Sensitive: D – Preclinical
selumetinib + MK-2206
Sensitive
:
D
selumetinib + MK-2206
Sensitive: D – Preclinical
selumetinib + MK-2206
Sensitive
:
D
PTEN R130del
Thyroid Gland Papillary Carcinoma
PTEN R130del
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
BRAF V600E
Colorectal Cancer
BRAF V600E
Colorectal Cancer
vemurafenib + MK-2206
Sensitive: D – Preclinical
vemurafenib + MK-2206
Sensitive
:
D
vemurafenib + MK-2206
Sensitive: D – Preclinical
vemurafenib + MK-2206
Sensitive
:
D
PIK3CA E545K
Breast Cancer
PIK3CA E545K
Breast Cancer
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
MK-2206 + D9
Sensitive: D – Preclinical
MK-2206 + D9
Sensitive
:
D
MK-2206 + D9
Sensitive: D – Preclinical
MK-2206 + D9
Sensitive
:
D
PTEN deletion
Melanoma
PTEN deletion
Melanoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
NRAS Q61R
Thyroid Gland Anaplastic Carcinoma
NRAS Q61R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
RET-PTC1 rearrangement
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
PIK3CA mutation
Thyroid Gland Carcinoma
PIK3CA mutation
Thyroid Gland Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
PIK3CA E545K
Thyroid Gland Papillary Carcinoma
PIK3CA E545K
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
PIK3CA H1047R
Thyroid Gland Anaplastic Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
RET rearrangement
Thyroid Gland Papillary Carcinoma
RET rearrangement
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
dasatinib + MK-2206
Sensitive: D – Preclinical
dasatinib + MK-2206
Sensitive
:
D
dasatinib + MK-2206
Sensitive: D – Preclinical
dasatinib + MK-2206
Sensitive
:
D
AKT1 Q79K
Melanoma
AKT1 Q79K
Melanoma
vemurafenib + MK-2206
Sensitive: D – Preclinical
vemurafenib + MK-2206
Sensitive
:
D
vemurafenib + MK-2206
Sensitive: D – Preclinical
vemurafenib + MK-2206
Sensitive
:
D
FGF4 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
FGF4 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
FGF3 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
FGF3 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
FGF19 amplification + HRAS Q61R + TP53 672+2T>G
Prostate Cancer
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
EGFRVIII overexpression
Glioblastoma
EGFRVIII overexpression
Glioblastoma
enzalutamide capsule + MK-2206
Sensitive: D – Preclinical
enzalutamide capsule + MK-2206
Sensitive
:
D
enzalutamide capsule + MK-2206
Sensitive: D – Preclinical
enzalutamide capsule + MK-2206
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login